Whalegun
Lobbying

Biohaven Pharmaceuticals's latest lobbying report covers Q2 2026, at $60K. The four quarters Q4 2025–Q3 2026 total $180K. Its first report covers Q4 2022; the issues it reports most are Health Issues.

Biohaven Pharmaceuticals

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$180K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Biohaven Pharmaceuticals lobbying by quarter
Biohaven Pharmaceuticals lobbying by quarter
QuarterAmountReports
Q4 2022$20K1
Q1 2023$50K1
Q2 2023$60K1
Q3 2023$60K1
Q4 2023$60K1
Q1 2024$60K1
Q2 2024$60K1
Q3 2024$60K1
Q4 2024$60K1
Q1 2025$60K1
Q2 2025$60K1
Q3 2025$60K1
Q4 2025$60K1
Q1 2026$60K1
Q2 2026$60K1
Q3 2026$00

By issue

  • Health issues$850K · 15 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • SENATE15 reports
  • HOUSE OF REPRESENTATIVES14 reports
  • Executive Office of the President (EOP)4 reports
  • Health & Human Services, Dept of (HHS)4 reports

Firms it paid

Firm
Dla Piper$850K15 quarters

Former officials lobbying for it

Former position
VINCENT SARUBBI jrDeputy Chief of Staff and Legislative Director, Rep. Josh Gottheimer; Legis. Assistant, Sen. Sherrod Brown; Senior Legislative Assistant, Rep. Donald Norcross; Legislative Assistant, Rep. Rob AndrewsQ1 2025

Lobbying reports

Filed by
07/20for Q2Dla Piper$60K
04/20for Q1Dla Piper$60K
01/16for Q4 2025Dla Piper$60K
25/10/17for Q3 2025Dla Piper$60K
25/08/13for Q4 2022Dla PiperUnder $5,000
25/07/21for Q2 2025Dla Piper$60K
25/04/21for Q1 2025Dla Piper$60K
25/01/17for Q4 2024Dla Piper$60K
24/10/21for Q3 2024Dla Piper$60K
24/07/22for Q2 2024Dla Piper$60K
24/04/19for Q1 2024Dla Piper$60K
24/01/22for Q4 2023Dla Piper$60K
23/10/20for Q3 2023Dla Piper$60K
23/07/20for Q2 2023Dla Piper$60K
23/04/20for Q1 2023Dla Piper$50K
23/01/20for Q4 2022Dla Piper$20K